Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

VB10.NEO

Vaccine · Immune activation, directed at neoantigens · developed by Nykode Therapeutics

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is VB10.NEO?

VB10.NEO is a vaccine supplied as a sterile, ready-to-use solution and given as a series of 14 vaccinations. It is studied in patients with locally advanced or metastatic solid tumours.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine
Targets
neoantigens (antigen)
Mechanism
Immune activation, directed at neoantigens
Therapy area
Oncology
Developer
Nykode Therapeutics ASA
In trials of
NKTR
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03548467 Phase 1/2 Locally Advanced or Metastatic Solid Tumours Completed NKTR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Locally Advanced or Metastatic Solid Tumours

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.